CDEK
← All organizations

Mirum Pharmaceuticals, Inc.

For profitContributed to NMEWebsite ↗

Also known as: MIRUM | Mirum Pharmaceuticals, Inc. | MIRUM PHARMA INC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Jul 31, 2019

First marketed drug

Jun 1, 2018

First NDA

Sep 29, 2021

Last known activity

Dec 31, 2025

Timeline

2010s

  1. Jun 1, 2018

    Mirum Pharmaceuticals, Inc.— Founded

2020s

  1. Sep 29, 2021

    maralixibat— NDA Organization

  2. Sep 29, 2021

    maralixibat— NDA Secondary Org

  3. May 23, 2022

    Satiogen Pharmaceuticals, Inc.— Acquired

  4. Feb 21, 2025

    chenodeoxycholic acid— Marketing Organization

Drugs by trial phase (5 distinct, 13 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 2 (2 own, 2 via acquisition)

Indications

Studied for

Marketed drugs (3)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Recent trials (12)

Details

Founded
San Diego, CA, US Jun 1, 2018
First NDA
Sep 29, 2021
Last known activity
Dec 31, 2025

Designations held

  • Orphan drug
  • Priority review
  • Breakthrough therapy